Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.

Ex-Prometheus team will use its big data platform to validate targets, select indications and optimize trial enrollment in the development of precision therapies for inflammatory and immune disorders.

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Acquisition activity in the biopharmaceutical sector saw a strong uptick in deal value and an exponential increase in total deal value during the fourth quarter, according to data from Evaluate.